GenomeDx Publishes First Study Suggesting Predictive Capabilities of Decipher Prostate Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb) – Researchers from GenomeDx Biosciences and elsewhere have published data showing that the company's 22-gene Decipher test can distinguish between prostate cancer patients at high and low risk for metastasis after surgery, and  mayfurther predict which patients would benefit from adjuvant radiation therapy or would do well with salvage treatment.

Separately, GenomeDx told GenomeWeb that it is planning to submit Decipher for regulatory approval with the US Food and Drug Administration, but did not elaborate on those plans.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.